Treatment
Intravenous thrombolysis clinical trials
We’re tracking 26 recruiting studies that include Intravenous thrombolysis, each written for real people, not researchers, below.
Recruiting studies
- NCT07294209RecruitingPhase 4
Low-dose tenecteplase for older adults with stroke
This trial tests a lower dose of the clot-busting drug tenecteplase in people aged 70 and older who have had an ischemic stroke. It aims to see if this treatment is safe and effective for older patients when given within 4.5 hours of symptoms starting.
Chongqing, Chongqing MunicipalityAges 70 years+ - NCT06749834RecruitingPhase 3
Clot-busting drug after stroke in people on newer blood thinners
This trial tests whether a clot-busting medication given through a vein (intravenous thrombolysis) can safely treat acute ischemic stroke within 24 hours in people who have taken a newer oral blood thinner (NOAC) within the last 4 to 48 hours.
Hangzhou, ZhejiangAges 18 years+ - NCT06131385Recruiting
Tracking IV clot-busting treatment for stroke in China
This study is tracking patients in southwestern China who have had an acute ischemic stroke and received a clot-busting medicine through an IV. It aims to learn more about how well this treatment works and how it is used in real-world settings.
LuzhouAges Any age - NCT07119021RecruitingPhase 4
Ultra-early stroke treatment with neuroprotection and clot removal
This trial tests a new approach for treating acute ischemic stroke within 4.5 hours of symptoms starting. It combines a special mobile stroke unit that delivers early brain-protecting medicine with standard clot-busting or clot-removal procedures, to see if this can improve recovery.
BeijingAges 18–80 - NCT07299994Recruiting
Intravenous thrombolysis for specific brain strokes
This trial tests whether a clot-busting drug given through a vein can help people with certain types of deep brain strokes that happen in small arteries. It looks at patients who can be treated within 24 hours of symptoms starting.
Vienna, State of ViennaAges 18 years+ - NCT07299981Recruiting
Brain water changes after clot-busting drug for stroke
This study looks at how much water builds up in brain tissue after a stroke is treated with a clot-busting drug. It may help doctors understand who will recover better.
ViennaAges 18 years+ - NCT05199662RecruitingPhase 3
IV clot-busting medicine for stroke when standard options don’t fit
This trial tests whether giving IV TNK (tenecteplase) plus standard stroke care can improve outcomes in some people who have a new stroke but cannot get alteplase (another clot-busting drug) and do not have a large blocked artery that can be treated with a procedure. It’s meant for strokes with “mismatch” findings on scans that suggest salvageable brain tissue.
Porto Alegre, Rio Grande do SulAges 18 years+ - NCT06559436Recruiting
Extending window for clot-busting drug in medium vessel stroke
This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.
Hefei, AnhuiAges 18 years+ - NCT06727006Recruiting
Rescue stenting and clot-dissolving medicine for severe stroke
This trial tests whether using a stent plus a clot-dissolving drug can improve outcomes for people with a large-vessel stroke who are having a procedure to remove the clot. It is designed for patients who can receive treatment within 24 hours of their first symptoms.
Bergamo, ItalyAges 18 years+ - NCT06571149RecruitingPhase 4
Blood thinners and clot-busting drugs for stroke
This trial tests whether giving a clot-dissolving medicine (alteplase or tenecteplase) is safe and effective for people who have had a stroke and are taking a blood thinner (DOAC) like apixaban or rivaroxaban. It aims to see if this treatment can still be given within a few hours of the stroke.
EisenstadtAges 18 years+ - NCT04624295RecruitingPhase 4
Aspirin soon after certain bleeding stroke, after clot-busting therapy
This trial studies whether starting aspirin early is safe and helpful for people who, after clot-busting treatment for an ischemic stroke, develop a specific type of small brain bleeding called hemorrhagic infarction. You might benefit if your scan later shows this pattern of bleeding and you are not able to take blood-thinners or aspirin is safe for you.
HangzhouAges Any age - NCT05741905Recruiting
Levofloxacin antibiotic with IV clot-busting for acute stroke
This trial tests whether adding the antibiotic levofloxacin to standard IV clot-busting treatment is safe and improves outcomes after an acute ischemic stroke. It may help by reducing complications related to infection or inflammation, but you must meet specific heart, liver, kidney, and medication-safety rules.
Changchun, JilinAges 18–75 - NCT05922540Recruiting
Study of ischemic stroke to improve patient care
This study looks at people who have had an ischemic stroke (a type caused by a blocked blood vessel). It is collecting information over time to better understand care needs and follow-up after stroke.
HunanAges 18 years+ - NCT06045156Recruiting
Tirofiban after clot-busting for stroke
This trial tests whether giving tirofiban (a blood thinner) shortly after the standard clot-busting drug tenecteplase can improve recovery from a moderate stroke. It is for people who have had a stroke within the last few hours and do not have certain risk factors like irregular heart rhythm or recent bleeding.
Changchun, JilinAges 18 years+ - NCT06157502RecruitingPhase 3
Shuxuening with clot-busting treatment for ischemic stroke
This trial tests if adding the herbal injection Shuxuening to standard clot-busting treatment improves recovery for people having an ischemic stroke. It is for adults within 6 hours of symptom onset who are already receiving a clot-dissolving medication.
Beijing, Beijing MunicipalityAges 18–100 - NCT06548971RecruitingPhase 3
Early antiplatelet after clot-busting for stroke (TREND-IVT)
This trial tests whether giving an antiplatelet medicine (like aspirin) early—within 3 hours of a clot-busting drug—can help prevent another stroke without causing bleeding. It is for people who still have moderate to severe stroke symptoms after the clot-buster and do not have a large artery blockage.
Bengbu, AnhuiAges 18 years+ - NCT06556446Recruiting
Clot-busting drug after stroke if on blood thinner
This study looks at whether giving a clot-busting medicine (IV thrombolysis) is safe and effective for people who have had a stroke and also recently took a direct oral anticoagulant (DOAC). If you've taken a DOAC in the last 48 hours, this trial may help doctors decide the best treatment for you.
InnsbruckAges 18 years+ - NCT07094763Recruiting
Tenecteplase for posterior stroke 4.5-24 hours after onset
This trial tests a clot-busting drug called tenecteplase for people who had a stroke affecting the back part of the brain (posterior circulation). It may be an option if you can get treatment between 4.5 and 24 hours after symptoms started.
HefeiAges 18–100 - NCT07290751RecruitingPhase 4
Adding tirofiban to clot-busting for stroke patients
This trial tests whether adding a second medicine (tirofiban) to standard clot-busting treatment can help people who are not improving after the first hour. It is for people with a moderate to severe stroke who are not candidates for a clot-removal procedure.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07526987RecruitingPhase 3
Minocycline to Help Recovery After Acute Stroke Treatment
This study tests whether an antibiotic called minocycline, given alongside standard stroke treatment (clot-busting medication), can help reduce brain damage and improve recovery. You would receive minocycline around the time of your clot-busting treatment.
Liaocheng, ShandongAges 18–80 - NCT07375966RecruitingPhase 2
Repeated clot-busting drug for stroke with large vessel block
This trial tests if giving a second dose of the clot-busting drug tenecteplase can help people whose stroke symptoms don't improve after the first dose, when a large or medium artery in the brain is still blocked. It may be an option for patients who cannot have a mechanical clot removal procedure.
Shenyang, LiaoningAges 18–80 - NCT07375953RecruitingPhase 2
Repeated clot-busting drug for stroke within 3 hours
This trial tests if giving a second dose of a clot-busting drug (tenecteplase) helps people who had a stroke and didn't improve much after the first dose. You must receive the second dose within 4.5 hours of your stroke symptoms starting.
Shenyang, None SelectedAges 18–80 - NCT07550296RecruitingPhase 2
Second IV Clot-Dissolving Treatment for Major Stroke
This trial tests giving a second dose of an IV clot-dissolving medicine (prourokinase) to patients who had a stroke from a large clot but didn't improve enough after the first dose. The goal is to see if a second dose within 6 hours of stroke onset can help more patients recover.
Shenyang, None SelectedAges 18–80 - NCT07419997Recruiting
Observational study on clot-busting drugs beyond the usual window
This study looks at patients who received a clot-busting drug (intravenous thrombolysis) for their stroke 4.5 to 24 hours after symptoms started. It aims to see how well this works and what happens to them, using data that has already been collected.
BeijingAges 18 years+
What Intravenous thrombolysis is being studied for
Conditions with recruiting Intravenous thrombolysis studies.
Common questions
- Are there clinical trials studying Intravenous thrombolysis?
- Yes. Clin2 currently lists 26 recruiting studies that include Intravenous thrombolysis, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Intravenous thrombolysis trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Intravenous thrombolysis an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Intravenous thrombolysis or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.